Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119652 · ClinicalTrials.gov registry record · Phase 3
Seroquel in Bipolar Depression Versus SSRI
A Phase 3 study of Depression and Bipolar Disorder, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
- 20
- Study locations
NCT00119652 is a Phase 3 study of Depression and Bipolar Disorder that has completed, run by AstraZeneca. The registered enrollment target is 676 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00119652, a Phase 3 study of Depression and Bipolar Disorder, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
Conditions Studied
Interventions
- DRUG paroxetine
- DRUG quetiapine fumarate (Seroquel)
- BEHAVIORAL mood stabilizing activity
Study Locations (20)
California
- Research Site - National City
- Research Site - San Clemente
- Research Site - San Diego
Florida
- Research Site - Maitland
- Research Site - Winter Park
Georgia
- Research Site - Atlanta
- Research Site - Smyrna
Illinois
- Research Site - Northfield
- Research Site - Oak Brook
Louisiana
- Research Site - New Orleans
- Research Site - Shreveport
Ohio
- Research Site - Cincinnati
- Research Site - Dayton
Arizona
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119652
The ClinicalTrials.gov registry entry for NCT00119652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which paroxetine is the first listed.
NCT00119652 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00119652 about?
NCT00119652 is a clinical study titled "Seroquel in Bipolar Depression Versus SSRI". The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
What is the current status of trial NCT00119652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2005-05. Estimated completion is 2007-05.
What conditions does trial NCT00119652 study?
This clinical trial studies the following conditions: Depression, Bipolar Disorder, Bipolar Depression.
What interventions are being tested in trial NCT00119652?
The interventions under investigation include: paroxetine (DRUG), quetiapine fumarate (Seroquel) (DRUG), mood stabilizing activity (BEHAVIORAL).
Who is sponsoring clinical trial NCT00119652?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00119652 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.